ClinicalTrials.gg
RecruitingNCT05246410Updated Nov 29, 2023

A Clinical Trial to Evaluate the Efficacy and Safety of a Spot Stent System Used in Femoropopliteal Arteries.

An interventional study of Spot stent system and Self-expanding peripheral stent system in Peripheral Vascular Disease (PVD) and Peripheral Arterial Disease (PAD), sponsored by Acotec Scientific Co., Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-29.

Primary conditionPeripheral Arterial DiseaseRegistry: Peripheral Vascular DiseasesReclassifiedWhy we changed it
Registry
Peripheral Vascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Peripheral Arterial Disease
Why
  1. The study's listed conditions name Peripheral Arterial Disease, a narrower term within Peripheral Vascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Acotec Scientific Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.

Planned enrollment
21st of 53
196 · median 167
Started
2022
with 7 others
No phase
34 of 80
13 open now
Primary completion
2024-11
later than 6 of 33 live
Registered
39th of 80
by date
Lead sponsor
7 of 80
Acotec Scientific Co., Ltd

Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 21st largest by planned enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2022, is one of 34 with no phase, reaches primary completion later than 6 of the 33 other live ones, and was the 39th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Peripheral Arterial Disease with a site in China, or all of them as a file.
02

Study summary

A prospective randomized trial designed to compare the efficacy and safety of spot stent system versus self-expanding peripheral stent system in the endovascular treatment of femoropopliteal arterial stenotic disease.

Read the detailed description

The objective of this clinical investigation is to assess the efficacy and safety of spot stent system ,which is indicated for use in patients with atherosclerotic disease of the superficial femoral artery (SFA) or proximal popliteal arteries and for the treatment of insufficient results after percutaneous transluminal angioplasty.

03

Conditions studied

  • Peripheral Vascular Disease (PVD)
  • Peripheral Arterial Disease (PAD)

Browse trials for

04

In context

Peripheral Arterial Disease Reclassified

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

This study's planned enrollment of 196 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

Acotec Scientific Co., Ltd is the lead sponsor of 17 studies on the registry; 8 are open to participants now.

Compared within Peripheral Arterial Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Vascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old and ≤80 years old
  • Had lower extremity arterial occlusive diseases, and Rutherford classification is 2-5
  • Target lesion is in the superficial femoral artery (SFA) and/or proximal popliteal artery (above the knee), located ≥1 cm below the common femoral artery (CFA) bifurcation to the distal segment of the proximal popliteal artery at the superior end of the patella.
  • Target lesion had severe stenosis (stenosis degree ≥70%) or occlusion.
  • Presence of at least one patent infrapopliteal vessel.
  • The length of target lesion ≥10 cm.
  • After predilation, the target lesion has \<30% residual stenosis and presence of at least one flow-limiting dissection (by visual estimate).
  • Subject (or legal guardian) understands the study requirements and procedures and provides written before any study tests or procedures are performed.

Exclusion criteria

Exclusion Criteria:

  • The plasma creatinine level is higher than 150 umol/L.
  • Thrombolysis or thrombectomy is required.
  • The patient had underwent lower-limb arterial surgery or thrombolysis on the target limb within 6 weeks.
  • Previously implanted stent in the target lesion.
  • The guide wire can not cross the target lesion.
  • Angiographic evidence of calcification severe enough that it renders the target lesion non-dilatable.
  • Patient has a known allergy to anticoagulant drugs, anti- drugs or contrast medium that cannot be adequately pre-medicated.
  • Women who are pregnant or breast-feeding.
  • The subjects have participated in other drug property studies or device studies that have not yet completed the main end point.
  • Patient has of less than 12 months.
  • Patient who planned to do above the ankle amputation before the operation.
  • Patient who had severe hemorrhage or coagulation disorder which judged by the investigator.
  • The investigator think the patient is not suitable for participation in the clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
196 participants (estimated)

Study arms

  • Experimental
    Spot stent system

    A system that loaded multi low radial force stents on one catheter.

    Device: Spot stent system

  • Active comparator
    Self-Expanding peripheral stent system

    A conventional stent system that commonly used.

    Device: Self-expanding peripheral stent system

Interventions

  • DeviceSpot stent system

    Spot stent system designed and produced by Acotec

  • DeviceSelf-expanding peripheral stent system

    Self-expanding peripheral stent system designed and produced by Ev3, Inc

07

What researchers measure

Primary outcomes

  1. The primary patency rate of target lesion at 12 months post-procedure

    Defined as freedom from clinically driven target lesion revascularization (CD-TLR) and binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4)

    Time frame: 12 months post-procedure

Secondary outcomes

  1. Rate of device success

    Defined as successful delivery, release and retrieval of the device.

    Time frame: immediate post-procedure

  2. Rate of procedural success

    Defined as no provisional stent implanted or major adverse event occured prior to discharge.

    Time frame: 7 days post-procedure

  3. Rate of clinically driven target lesion revascularization within 12 months post-procedure

    Defined as any reintervention at the target lesion due to the following symptoms: drop of ABI \>20% or ABI \>0.15 compared to the post-procedure ABI

    Time frame: 12 months post-procedure

  4. The change of Rutherford class from baseline

    Defined as change in target limb Rutherford class from baseline to 12 months

    Time frame: 12 months post-procedure

  5. The change of ankle-brachial index (ABI) from baseline

    Defined as change of target limb ABI from baseline to 12 months

    Time frame: 12 months post-procedure

  6. Rate of composite safety endpoint

    Defined a composite rate of all cause death, major target limb amputation (above-the-ankle amputation), clinically driven target lesion revascularization (CD-TLR) through 30 days post- procedure

    Time frame: 30 days post-procedure

08

Study locations

2 of 2 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Nov 2024, 27 months after the start.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 27 months is close to that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Feb 18, 2022
StartActual
Aug 17, 2022
Primary completionEst.
Nov 28, 2024
CompletionEst.
Dec 30, 2024
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05246410
Lead sponsor
Acotec Scientific Co., Ltd
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Aug 17, 2022
Primary completion
Nov 28, 2024 (estimated)
Completion
Dec 30, 2024 (estimated)
Last update
Nov 29, 2023

Study contacts

Guo Wei, MD
Contact
pla301dml@vip.sina.com
010-66887329
Guo Wei, MD
principal investigator · Chinese PLA General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion